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Abstract
Cathepsin B (CTSB) is a proteolytic enzyme potentially modulating angiogenic processes and extracellular matrix
remodeling. While matrix metalloproteinases are shown to be implicated in tissue fibrosis and vasculopathy associated with
systemic sclerosis (SSc), the role of cathepsins in this disease has not been well studied. The aim of this study is to evaluate
the roles of CTSB in SSc. Serum pro-CTSB levels were determined by enzyme-linked immunosorbent assay in 55 SSc patients
and 19 normal controls. Since the deficiency of transcription factor Fli1 in endothelial cells is potentially associated with the
development of SSc vasculopathy, cutaneous CTSB expression was evaluated by immunostaining in Fli1
+/2 and wild type
mice as well as in SSc and control subjects. The effects of Fli1 gene silencing and transforming growth factor-b (TGF-b)o n
CTSB expression were determined by real-time PCR in human dermal microvascular endothelial cells (HDMECs) and dermal
fibroblasts, respectively. Serum pro-CTSB levels were significantly higher in limited cutaneous SSc (lcSSc) and late-stage
diffuse cutaneous SSc (dcSSc) patients than in healthy controls. In dcSSc, patients with increased serum pro-CTSB levels
showed a significantly higher frequency of digital ulcers than those with normal levels. CTSB expression in dermal blood
vessels was increased in Fli1
+/2 mice compared with wild type mice and in SSc patients compared with healthy controls.
Consistently, Fli1 gene silencing increased CTSB expression in HDMECs. In cultured dermal fibroblasts from early dcSSc,
CTSB expression was decreased compared with normal fibroblasts and significantly reversed by TGF-b1 antisense
oligonucleotide. In conclusion, up-regulation of endothelial CTSB due to Fli1 deficiency may contribute to the development
of SSc vasculopathy, especially digital ulcers, while reduced expression of CTSB in lesional dermal fibroblasts is likely to be
associated with skin sclerosis in early dcSSc.
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Introduction
Systemic sclerosis (SSc) is a multisystem autoimmune disease
characterized by initial vascular injuries and resultant fibrosis of
skin and certain internal organs [1]. Although the pathogenesis of
SSc still remains unknown, an increasing number of growth
factors, cytokines, and other molecules have been shown to be
involved in the orchestrated complex network of signaling
pathways driving aberrant immune activation, dysregulated
angiogenesis, and deposition of extracellular matrix (ECM)
throughout the course of this complex disorder [2,3].
Cathepsins are a family of proteases mostly consisting of
papain-like cysteine proteases, which are mainly localized in
e n d o s o m e sa n dl y s o s o m e s[ 4 ] .H o w e v e r ,c a t h e p s i n sa l s of u n c t i o n
extracellularly and are involved in various biological processes,
including ECM degradation, angiogenesis, and tumor invasion
[4,5]. Some of the cathepsins (B, H, L, and C) are constitutively
expressed in all cell types and tissues, whereas others are present
in specific cell types (cathepsins S, V, X, O, K, F, and W) [5].
While matrix metalloproteinases (MMPs) are shown to be
implicated in tissue fibrosis and vasculopathy associated with
SSc, the role of cathepsins in this disease has not been well
studied.
Among the member of cathepsin family, the roles of CTSB
have been well studied in fibrosis and angiogenesis. In a murine
model of liver fibrosis caused by CCl4, CTSB expression
increases in hepatic stellate cells and its inactivation mitigates
CCl4-induced inflammation, hepatic stellate cell activation, and
collagen deposition [6]. Regarding angiogenesis, murine CTSB in
vasculature is remarkably up-regulated during the degradation of
vascular basement membrane associated with tumor angiogenesis
[7]. In glioma cell lines, CTSB knockdown inhibits tumor-
induced angiogenesis by modulating the expression of vascular
endothelial growth factor (VEGF) [8]. In contrast to these
observations, CTSB also has the capacity to suppress pro-
angiogenic response, probably as a negative feedback control, by
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genesis inhibitor derived from the breakdown of type XVIII
collagen, while decreasing VEGF expression [9]. Importantly,
serum endostatin levels are increased in SSc patients and
associated with the presence of skin sclerosis, giant capillaries in
nailfold capillaroscopy, cardiovascular changes, and pulmonary
vascular involvement [10–14], suggesting that CTSB contributes
to the pathological processes associated with fibrosis and
vasculopathy at least partially via modulating endostatin
production.
Based on these backgrounds, in order to clarify the role of
CTSB in the development of SSc, we herein investigated the
association of serum pro-CTSB levels with clinical features of SSc
and also examined the possible mechanism responsible for the
altered expression of CTSB in this disease.
Materials and Methods
Ethics Statement
The study protocol was reviewed and approved by the Ethical
Committee of the Faculty of Medicine, University of Tokyo.
Serum samples, skin tissue, and dermal fibroblasts were obtained
from systemic sclerosis patients and healthy individuals after
getting written informed consent. Human dermal microvascular
endothelial cells (HDMECs) were purchased from Takara Bio
(Shiga, Japan). All animal work was reviewed and approved by
Animal Research Committee of the Faculty of Medicine,
University of Tokyo.
Patients
Serum samples, frozen at 280uC until assayed, were obtained
from 55 SSc patients (52 women and 3 men, including 27 diffuse
cutaneous SSc [dcSSc] and 28 limited cutaneous SSc [lcSSc]
according to LeRoy’s classification [15]) and 19 healthy
individuals (18 women, one man). Patients treated with cortico-
steroids or other immunosuppressants were excluded. All patients
fulfilled the American College of Rheumatology criteria [16]
except for 4 lcSSc patients who had sclerodactyly and at least two
other features of CREST syndrome.
The measurement of serum pro-CTSB levels
Specific enzyme-linked immunosorbent assay kits were used to
measure serum pro-CTSB levels (R & D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instruction.
Clinical assessment
The clinical and laboratory data were obtained when the blood
samples were drawn. Clinical symptoms were evaluated as
described previously [17–20]. The details of assessments are
briefly summarized in the legends of Table 1.
Immunohistochemistry
Immunohistochemistry with Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) was performed on forma-
lin-fixed, paraffin-embedded tissue sections using anti-human
CTSB antibody (R & D Systems) or anti-mouse CTSB antibody
(Santa Cruz, Santa Cruz, CA, USA). Skin samples were obtained
from forearms of 8 SSc patients and 8 closely matched healthy
controls and from the back of 3-month-old mice.
Cell cultures
HDMECs and human dermal fibroblasts were prepared and
maintained as described previously [21,22].
Gene silencing of Fli1 and the treatment with TGF-b1o r
TGF-b1 antisense oligonucleotide
These experiments were performed as described previously
[21,23]. The details of each experiment are described in figure
legends.
RNA isolation and quantitative real-time PCR
RNA isolation and quantitative real-time PCR were carried out
as described previously [22]. The sequences of CTSB [24], Fli1
[25] and 18S rRNA [26] primers were previously reported.
Table 1. Correlation of serum pro-cathepsin B levels with
clinical features in patients with dcSSc and lcSSc.
dc/lc SSc dcSSc lcSSc
Serum pro-CTSB levels Elevated Normal Elevated Normal
The number of patients n=4 n=23 n=8 n=20
Age of onset (years old) 54.5616.8 47.7616.5 53.9618.8 51.8615.5
Disease duration (years) 6.363.9 2.762.8 9.4610.0 12.2613.1
Clinical features
MRSS 9.869.1 11.767.5 3.061.7 4.865.1
Nailfold bleeding 50 71 63 68
Pitting scars 50 26 50 29
Digital ulcers 75* 9 0 29
Telangiectasia 25 47 60 50
Raynaud’s phenomenon 75 86 88 88
Contracture of phalanges 25 57 40 54
Calcinosis 25 0 17 17
Organ involvement
ILD 75 65 13 25
Decreased %DLco 25 30 50 28
Decreased %VC 0 19 13 15
Elevated RVSP 50 17 29 32
Esophagus 25 60 38 51
Heart 25 0 0 2
Kidney 25 4 25 7
Muscle 25 5 17 6
Unless noted otherwise, values are percentages. dcSSc, diffuse cutaneous
systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; MRSS, modified
Rodnan total skin thickness score; DLco, diffuse capacity for carbon monoxide;
VC, vital capacity; RVSP; right ventricular systolic pressure. Patients were
evaluated for the presence of esophageal, pulmonary, cardiac, renal, or muscle
involvements, as follows. Esophagus hypomotility was defined as distal
esophageal hypomotility on barium-contrast radiography. Interstitial lung
disease (ILD) was defined as bibasilar interstitial fibrosis on chest radiographs,
and in patients with no abnormalities on chest radiographs early ILD was
defined as alveolitis on high-resolution computer tomography. Elevated right
ventricular systolic pressure (RVSP) was defined as 35 mmHg or more on
echocardiogram. Cardiac involvement was defined as any of the following:
symptomatic pericarditis, clinical evidence of left ventricular congestive heart
failure, or arrhythmias requiring treatment. Scleroderma renal crisis was defined
as malignant hypertension and/or rapidly progressive renal failure. Skeletal
muscle involvement was defined as proximal muscle weakness and elevated
serum creatine kinase levels, plus abnormal electromyographic findings
consistent with myopathy and/or histopathologic changes in inflammatory
myopathy. Disease onset was defined as the first clinical event of SSc other than
Raynaud’s phenomenon. Disease duration was defined as the interval between
the onset and the time the blood samples were drawn. Statistical analysis was
carried out with Fisher’s exact probability test.
*P,0.05.
doi:10.1371/journal.pone.0032272.t001
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Fli1 heterozygous mice with C57BL/6J background were
provided from Prof. Maria Trojanowska (Boston University
School of Medicine, Arthritis Center, Boston, MA, USA) [27].
Statistical analysis
The statistical analysis carried out in each experiment is
described in figure legends or ‘‘Results’’. Statistical significance
was defined as a P value of ,0.05.
Results
Serum pro-CTSB levels were significantly increased in SSc
patients compared to healthy controls
Serum pro-CTSB levels in SSc patients were significantly higher
than those in healthy individuals (62.2630.7 versus
44.4618.7 ng/ml; P,0.05). Since the expression profiles of
certain growth factors and cytokines can be quite different
between dcSScand lcSSc, we also evaluated serum pro-CTSB
levels in these subgroups. As shown in Fig. 1, serum pro-CTSB
levels were significantly higher in lcSSc patients (66.2632.3 ng/
ml) than in healthy controls (P,0.05), while there was a trend
toward the elevation in dcSSc patients (58.1628.9 ng/ml)
compared with healthy controls that did not reach significance.
Collectively, the increase in serum pro-CTSB levels may be
associated with some aspects of disease process in SSc.
Clinical association of serum pro-CTSB levels in lcSSc
Since lcSSc patients showed significantly higher serum pro-
CTSB levels compared to healthy controls, we next classified
lcSSc patients into two groups based on the cut-off value
(81.8 ng/ml, normal mean+2SD), such as lcSSc patients with
increased serum pro-CTSB levels and those with normal levels,
and assessed the correlation of serum pro-CTSB levels with
clinical features (right columns in Table 1). However, we failed
to detect the correlation of serum pro-CTSB levels with any
clinical features, suggesting that the increase in CTSB is not
associated with any specific pathological process leading to each
clinical feature in lcSSc.
Serum pro-CTSB levels were significantly increased in
late-stage dcSSc patients compared to early-stage dcSSc
patients or healthy controls
We next focused on dcSSc patients because serum pro-CTSB
levels tended to be increased in this subgroup compared with
healthy controls. Since dcSSc is characterized by progressive skin
sclerosis and ILD, we evaluated the association of serum pro-
CTSB levels with parameters reflecting the degree of fibrosis in
skin and lung, such as modified Rodnan total skin thickness score
(MRSS), %VC, and %DLco. Despite its pro-fibrotic effect, none
of these three parameters correlated with serum pro-CTSB levels
in dcSSc (r=0.08, 0.009, and 0.03, respectively). According to
previous reports, the expression profile of proteolytic enzymes can
be altered along with the disease duration in dcSSc. For example,
although the mRNA levels of MMP1 gene in SSc dermal
fibroblasts from patients with disease duration of ,1 year are
significantly higher than those in normal dermal fibroblasts, SSc
dermal fibroblasts from patients with disease duration of 2–4 years
show low mRNA levels of MMP1 gene compared with normal
dermal fibroblasts. Furthermore, the mRNA levels of MMP1 gene
in SSc dermal fibroblasts from patients with disease duration of
more than 6 years were comparable to those in normal dermal
fibroblasts [28]. Therefore, we classified dcSSc patients into 3
subgroups based on disease duration, such as early-stage dcSSc
(disease duration of ,1 year), mid-stage dcSSc (disease duration of
1 to 6 years), and late-stage dcSSc (disease duration of .6 years),
and evaluated the correlation of serum pro-CTSB levels with
disease duration. As shown in Fig. 2, serum pro-CTSB levels were
increased in late-stage dcSSc patients (86.4633.6 ng/ml) com-
pared with early-stage dcSSc patients (35.7621.3 ng/ml) and
healthy individuals (P,0.05 for each), while there was no
significant difference between early-stage dcSSc or mid-stage
dcSSc patients (57.7623.1 ng/ml) and healthy individuals.
Consistently, there was a strong positive correlation between
serum pro-CTSB levels and disease duration in dcSSc patients
(r=0.50, P,0.01, Spearman’s rank correlation coefficient). Thus,
serum pro-CTSB levels gradually increased along with disease
duration in dcSSc, suggesting that CTSB may be linked to certain
clinical features which develop or get worse in the late stage of
dcSSc. Alternatively, downregulation of CTSB in early dcSSc
compared with late-stage dcSSc or lcSSc may reflect the
extensively activated fibrotic response in early dcSSc.
Elevated serum pro-CTSB levels were associated with the
development of digital ulcers in dcSSc
To further investigate the association of serum pro-CTSB levels
with clinical manifestations in dcSSc other than skin fibrosis and
Figure 1. Serum pro-CTSB levels in patients with dcSSc, lcSSc,
and healthy individuals. Serum pro-CTSB levels were determined by
a specific ELISA. Bars indicate the mean value in each group. Statistical
analysis was carried out with a Kruskal-Wallis test and a Steel-Dwass’
test for multiple comparison. *P,0.05.
doi:10.1371/journal.pone.0032272.g001
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cut-off value and analyzed (the left column in Table 1). There was
no significant difference between these two groups in terms of sex,
age, and disease duration. The frequency of digital ulcers was
significantly higher in patients with increased serum pro-CTSB
levels than in those with normal levels (75% versus 8.7%,
P=0.013). Although digital ulcers in dcSSc patients are closely
related to macrovascular involvements resulting from proliferative
vasculopathy [29], there was no significance difference in the
prevalence of elevated right ventricular systolic pressure (RVSP)
and scleroderma renal crisis, which are also caused by proliferative
vasculopathy [30,31], between these two groups [32]. Regarding
other clinical features, we failed to detect any correlation with
serum pro-CTSB levels. Collectively, these results suggest that
elevation of CTSB contributes to the pathological process
associated with digital ulcers in dcSSc.
Comparison of the CTSB expression in skin sections
derived from SSc patients and healthy controls
As described above, CTSB is potentially associated with the
disease process of SSc, especially fibrosis and vasculopathy. To
further confirm this notion, immunohistochemistry was carried out
using skin samples from 5 dcSSc and 3 lcSSc patients and 8
healthy controls. Clinical information and the results were
summarized in Table 2. In normal skin sections, CTSB staining
was especially strong in small blood vessels consisting of
endothelial cells (ECs) and pericytes/vascular smooth muscle cells
compared to other cell types (Fig. 3A and 3B). Although a similar
predominant distribution of CTSB in blood vessels was observed
in SSc skin sections, the signals were much stronger than those in
normal skin sections (Fig. 3C and 3D). Importantly, there was no
remarkable difference in CTSB signals between dcSSc and lcSSc.
These results suggest that CTSB is up-regulated in dermal blood
vessels in SSc and plays some roles in the developmental process of
SSc vasculopathy.
CTSB was down-regulated in SSc dermal fibroblasts due
to the constitutive activation of TGF-b signaling
Although the CTSB expression in blood vessels was similar
between dcSSc and lcSSc, serum pro-CTSB levels were decreased
in early dcSSc compared with late-stage dcSSc and lcSSc. Given
that lesional dermal fibroblasts are extensively activated in early
dcSSc, the dynamics of serum pro-CTSB levels along with disease
duration in dcSSc may be linked to the activation status of SSc
dermal fibroblasts. Since CTSB signals in dermal fibroblasts were
below the detectable levels in immunohistochemistry (Fig. 3), we
next investigated the mRNA levels of CTSB gene in cultured
normal and SSc dermal fibroblasts. As shown in Fig. 4A, SSc
fibroblasts expressed significantly lower mRNA levels of CTSB
gene than normal fibroblasts. Since SSc dermal fibroblasts are
constitutively activated by the stimulation of autocrine TGF-b
[21,33–35], we asked if CTSB down-regulation depends on
autocrine TGF-b stimulation in SSc fibroblasts. To this end, we
employed TGF-b1 antisense oligonucleotide, which effectively
blocks endogenous TGF-b production in dermal fibroblasts [33–
35]. As expected, TGF-b1 antisense oligonucleotide, but not TGF-
b1 sense oligonucleotide, significantly increased the mRNA levels
of CTSB gene in SSc fibroblasts (Fig. 4B). Furthermore, TGF-b1
stimulation significantly suppressed the mRNA expression of
CTSB gene in normal fibroblasts (Fig. 4C). Collectively, CTSB
expression is decreased in lesional dermal fibroblasts of early
dcSSc as a result of autocrine TGF-b stimulation. Given the
implication of TGF-b in the pathogenesis of early dcSSc, but not
late-stage dcSSc [36], CTSB produced by dermal fibroblasts may
affect serum pro-CTSB levels in dcSSc throughout the disease
course.
Figure 2. Serum pro-CTSB levels in dcSSc patients further
classified into subgroups based on disease duration. dcSSc
patients were divided into 3 subgroups: those with disease duration of
,1 years, those with disease duration of 1 to 6 years, and those with
disease duration of .6 years. Serum pro-CTSB levels were determined
by a specific ELISA. The horizontal bars indicate the mean value in each
group. Statistical analysis was carried out with a Kruskal-Wallis test and
a Steel-Dwass’ test for multiple comparison. *P,0.05.
doi:10.1371/journal.pone.0032272.g002
Table 2. Cathepsin B levels in dermal vasculature in normal
and systemic sclerosis skin.
Samples Age/sex Duration (years) dcSSc/lcSSc Signal intensity
NS1 65F 2
SSc1 61F 1 dcSSc +
NS2 63F +
SSc2 64F 0.5 dcSSc +++
NS3 40F +
SSc3 43F 2.6 dcSSc +++
NS4 55F 2
SSc4 56F 1.5 dcSSc ++
NS5 64M ++
SSc5 59M 0.5 dcSSc ++
NS6 56F +
SSc6 52F 1 lcSSc ++
NS7 55F +
SSc7 51F 0.2 lcSSc ++
NS8 59F +
SSc8 58F 1 lcSSc ++
NS, normal skin; SSc, systemic sclerosis; dcSSc, diffuse cutaneous systemic
sclerosis; lcSSc, limited cutaneous systemic sclerosis. We used the following
grading system: 2, no staining; +, slight staining; ++, moderate staining; +++,
strong staining.
doi:10.1371/journal.pone.0032272.t002
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regulation of CTSB in dermal blood vessels in animal
models
Finally, we further sought the mechanism by which CTSB is up-
regulated in SSc dermal blood vessels. We previously demonstrat-
ed that the deficiency of transcription factor Fli1 in endothelial
cells is potentially associated with the development of SSc
vasculopathy [22]. Therefore, we carried out immunostaining
for CTSB using skin sections from Fli1
+/2 mice and wild type
mice. As expected, CTSB expression was much higher in blood
vessels of Fli1
+/2 mice than in those of wild type mice (Fig. 5A
and 5B), suggesting that Fli1 regulates the expression of CTSB in
ECs. To further confirm this notion in vitro, we looked at the effect
of Fli1 gene silencing on the mRNA levels of CTSB gene in
HDMECs. As shown in Fig. 5C, ,50% knockdown of Fli1
resulted in the significant increase of CTSB mRNA levels (34%
increase, P,0.05). Collectively, these results indicate that Fli1
deficiency is at least partially involved in the mechanism of CTSB
up-regulation in SSc vasculature.
Discussion
This study was undertaken to clarify the contribution of CTSB,
a proteolytic enzyme related to fibrosis and angiogenesis, in the
pathogenesis of SSc. As an initial step to address this issue, we
investigated the serum pro-CTSB levels and their association with
clinical features in SSc. As expected, serum pro-CTSB levels were
significantly increased in lcSSc and tended to be elevated in dcSSc
compared to healthy controls. In lcSSc, we failed to detect any
correlation of serum CTSB levels with clinical features, suggesting
that CTSB elevation is associated with the development of lcSSc,
but not with any specific clinical features. In contrast, in dcSSc,
there was a strong positive correlation between serum pro-CTSB
levels and disease duration (r=0.50, P,0.01). Importantly, serum
pro-CTSB levels were significantly elevated in late-stage dcSSc
compared with healthy controls and dcSSc patients with elevated
pro-CTSB levels had a significantly higher prevalence of digital
ulcers than those with normal levels. Given that digital ulcers in
dcSSc are closely associated with macrovascular involvements
caused by proliferative vasculopathy [32], we also evaluated the
association of serum pro-CTSB levels with other vascular
symptoms associated with proliferative vasculopathy, such as
elevated RVSP and scleroderma renal crisis, but did not see any
correlation. Collectively, these results suggest that elevation of
CTSB contributes to the pathological process leading to SSc
vasculopathy, especially to digital ulcers in dcSSc.
Although the pathogenesis of SSc vasculopathy still remains
unknown, we recently demonstrated that endothelial Fli1
deficiency is potentially associated with the development of
vascular changes characteristic for SSc [22,37]. Endothelial cell-
specific Fli1 knockout (Fli1 ECKO) mice reproduce the patholog-
ical and morphological features of SSc vasculopathy, such as
stenosis of arterioles, dilation capillaries, and increased vascular
permeability. Gene silencing of Fli1 in HDMECs results in the
down-regulation of molecules regulating EC-EC interaction,
including PECAM-1 and VE-Cadherin, and those regulating
EC-pericyte interaction, including VE-Cadherin, S1P1, and
platelet-derived growth factor-B, and in the up-regulation of
Figure 3. CTSB expression was up-regulated in dermal vasculatures of SSc patients compared to those in controls. CTSB expression
levels in dermal vasculatures were determined by immunohistochemistry in skin section from 8 healthy control subjects (A, B) and 8 SSc patients (C,
D). Representative results are shown. Original magnification was 6200 (A, C) and 6400 (B, D). Analysis of CTSB expression levels in vessel walls is
included in Table 2.
doi:10.1371/journal.pone.0032272.g003
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brane (vBM). Furthermore, Fli1 deficiency promotes endothelial
proliferation and survival [38], probably linked to the development
of arteriolar stenosis, which is similar to proliferative vasculopathy
in SSc, in Fli1 ECKO mice. As shown in the present study, Fli1
gene silencing up-regulated the expression of CTSB in HDMECs
and Fli1
+/2 mice exhibited high expression levels of CTSB in
dermal vasculature. These results indicate that the elevation of
endothelial CTSB expression is included in the gene program
triggered by Fli1 deficiency in SSc. Given that CTSB is proteolytic
enzyme expressed at high levels in vasculature during vBM
degradation associated with tumor angiogenesis [7], CTSB
promotes the degradation of vBM together with other proteolytic
enzyme such as MMP9 in SSc [39]. Consistent with this notion,
we and others demonstrated that components of dermal vBM are
altered in SSc [22,40,41]. Thus, proteolytic activity of CTSB may
be associated with the mechanism responsible for vascular fragility
in SSc.
In addition to vBM degradation, CTSB modulates angiogen-
esis via the generation of endostatin from type XVIII collagen
and the suppression of endothelial VEGF production [9,42].
Given that Fli1 downregulation activates angiogenic process,
Figure 4. CTSB mRNA expression in SSc dermal fibroblasts was down-regulated due to constitutively activated TGF-b signaling.
mRNA levels of CTSB gene were determined by real-time PCR in confluent quiescent dermal fibroblasts from 9 SSc patients and 5 healthy controls (A),
in confluent quiescent dermal fibroblasts from 4 SSc patients and 4 healthy controls treated with a TGF-b1 antisense oligonucleotide
(GAGGGCGGCATGGGGAGG; AS-TGF-b1), which overlaps the promoter and transcriptional start site of the TGF-b1 gene, or a TGF-b1 sense
oligonucleotide (S-TGF-b1) as a control for 48 hours (B), and in normal dermal fibroblasts stimulated with recombinant human TGF-b1 (PeproTech,
Rocky Hill, NJ, USA) at 10 ng/ml for 24 hours (C). In real-time PCR, the mRNA levels of target genes were normalized to the levels of human 18S rRNA
gene. Results of controls or relative value compared with the controls are expressed as means 6 SD. Statistical analysis was carried out with a 2-tailed
unpaired (A) or paired (B, C) t-test. *P,0.05.
doi:10.1371/journal.pone.0032272.g004
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+/2 mice and in Fli1 siRNA-treated HDMECs.
Immunodetection of CTSB proteins in the skin sections of 3 month-old wild type (A) and Fli1
+/2 (B) mice (original magnification was 640) by
Vectastain ABC kit according to the manufacturer’s instruction. Insets (original magnification was 640) depict representative arterioles (panel 1),
venules (panel 2), and capillaries (panel 3; red arrowheads), respectively. Representative results in 5 wild type and 5 Fli1
+/2 mice are shown. (C)
HDMECs were seeded shortly before transfection. The cells were transfected with 10 nM of Fli1 and scrambled non-silencing siRNA (Santa Cruz) using
HiPerfect transfection reagent (Qiagen, Valencia, CA, USA) for 72 hours. Cells were then serum starved for the last 24 hours. mRNA levels of Fli1 and
CTSB genes were examined by quantitative real-time PCR and normalized to the levels of human 18S rRNA gene. Results of controls or relative value
compared with the controls are expressed as means 6 SD of 3 independent experiments. Statistical analysis was carried out with a 2-tailed paired t-
test. *P,0.05, **P,0.005.
doi:10.1371/journal.pone.0032272.g005
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negative feedback control of angiogenesis through endostatin
generation and VEGF suppression. Angiogenesis is a dynamic
process regulated by various pro-angiogenic and angiostatic
cytokines and growth factors, which are normally tightly
regulated both spatially and temporally. Therefore, the constitu-
tive up-regulation of CTSB in SSc vasculature itself means
impaired vascular homeostasis in this disease. Although the role
of CTSB in SSc vasculopathy still remains unknown, the high
prevalence of digital ulcers in dcSSc patients with elevated serum
pro-CTSB levels implies the significant role of CTSB in the
pathological vascular changes resulting in digital ulcers. Further
studies are currently on going in our laboratory.
Although serum pro-CTSB levels were decreased in early dcSSc
compared with lcSSc, CTSB signals in vasculature were
comparable between early dcSSc and lcSSc. A plausible
explanation for this observation is that the expression levels of
CTSB in dermal fibroblasts affect serum pro-CTSB levels in
dcSSc. Consistent with our hypothesis, the levels of CTSB were
decreased in dermal fibroblasts derived from early dcSSc due to
autocrine TGF-b stimulation. Given that TGF-b appears to be
sequestered in lesional skin of early dcSSc, but not in that of late-
stage dcSSc and lcSSc, and stimulate dermal fibroblasts [36], the
dynamics of serum pro-CTSB levels along with disease duration in
dcSSc may be attributable to CTSB levels from lesional dermal
fibroblasts. Given that a prominent proteolytic activity of CTSB,
the decrease in CTSB expression may contribute to the
progression of dermal fibrosis in early dcSSc.
In summary, we herein reported the first study regarding the
potential role of CTSB in the pathogenesis of SSc. Up-regulated
expression of CTSB in ECs and downregulation of CTSB in
dermal fibroblasts may contribute to pathological angiogenesis and
fibrosis in SSc. This study provides a new idea that the members of
cathepsin family as well as MMPs have pivotal roles in the
pathogenesis of SSc.
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